From the July 2015 issue of HealthCare Business News magazine
Continuous monitoring
device for peripheral IVs
Continuous monitoring device for peripheral IVs
The FDA recently approved a new continuous monitoring device, ivWatch Model 400, developed by ivWatch LLC that has the potential to reduce medication dosing errors by rapidly spotting common adverse events before they become dire. The device consists of an optical sensor and a patient monitor. The sensor uses visible and near infrared light to illuminate the tissue by the IV site, and then the patient monitor uses a proprietary algorithm to analyze the light reflected from the tissue. A clinician is then alerted if an adverse event has occurred. The device underwent extensive testing with a focus on hardware and software, patient dynamics and clinician workflow. To date, it has more than 75 utility patent applications filed worldwide.
New automated
interface for
device testing
New automated interface for device testing
A new approach to medical device testing in hospitals is available following the launch of the EQ2 Rigel SA Interface developed by Rigel Medical and EQ2. A new module has been incorporated into EQ2’s HEMS Enterprise software to make it fully compatible with the automated Rigel analyzer. This module enables the biomed engineer to harness the 288’s full capabilities to capture valuable information at the point of testing in a hospital or health care center before sending the data automatically to the HEMS system to complete safety checks and link to the medical device’s inventory, test library, and performance history.
Back to HCB News
